ArticleJournal of translational medicine2012
T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy.
Article in Journal of translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Adoptive T-cell Immunotherapy: Perfecting Self-Defenses.Experientia supplementum (2012) · 2022Article
- Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment.Cellular & molecular immunology · 2021Review
- Tumor-infiltrating lymphocytes in primary tumors of colorectal cancer and their metastases.Experimental and therapeutic medicine · 2019Article
- Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer.Frontiers in oncology · 2019Review
- Innate immunity and HPV: friends or foes.Clinics (Sao Paulo, Brazil) · 2018Article
- Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.Melanoma research · 2018Review
- Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.Medical oncology (Northwood, London, England) · 2018Review
- TGF-β-responsive CAR-T cells promote anti-tumor immune function.Bioengineering & translational medicine · 2018Article
- Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.Medical oncology (Northwood, London, England) · 2018Review
- Platelets subvert T cell immunity against cancer via GARP-TGFβ axis.Science immunology · 2017Article
- Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.Frontiers in immunology · 2017Review
- Review
- Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing.PloS one · 2014Article
- Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice.ACS nano · 2013Article
- The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells.BMC immunology · 2013Article
- Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer.American journal of translational research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Tumor antigen-reactive T cells must enter into an immunosuppressive tumor microenvironment, continue to produce cytokine and deliver apoptotic death signals to affect tumor regression. Many tumors produce transforming growth factor beta (TGFβ), which inhibits T cell activation, proliferation and cytotoxicity. In a murine model of adoptive cell therapy, we demonstrate that transgenic Pmel-1 CD8 T cells, rendered insensitive to TGFβ by transduction with a TGFβ dominant negative receptor II (DN), were more effective in mediating regression of established B16 melanoma. Smaller numbers of DN Pmel-1 T cells effectively mediated tumor regression and retained the ability to produce interferon-γ in the tumor microenvironment. These results support efforts to incorporate this DN receptor in clinical trials of adoptive cell therapy for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.